Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00202800 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Corewell Health West.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00202800 is a Phase 2 study that has completed, run by Corewell Health West. The registered enrollment target is 40 participants.
The verdict
NCT00202800, a Phase 2 study, has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer.
Interventions
- DRUG Gemcitabine, Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-03 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00202800
The ClinicalTrials.gov registry entry for NCT00202800 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health West, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, Etoposide is the first listed.
NCT00202800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00202800 about?
NCT00202800 is a clinical study titled "Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer". Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and...
What is the current status of trial NCT00202800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-03. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00202800?
The interventions under investigation include: Gemcitabine, Etoposide (DRUG).
Who is sponsoring clinical trial NCT00202800?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.